H

Hugel Inc
KOSDAQ:145020

Watchlist Manager
Hugel Inc
KOSDAQ:145020
Watchlist
Price: 279 500 KRW -0.36% Market Closed
Market Cap: 3.5T KRW
Have any thoughts about
Hugel Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

18
Current
11.3
Median
4.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
18
=
Enterprise Value
3.1T KRW
/
EBITDA
172.6B KRW
All Countries
Close
Market Cap EV/EBITDA
KR
Hugel Inc
KOSDAQ:145020
3.5T KRW 18
FR
Pharnext SCA
OTC:PNEXF
6T USD -219 476
US
Abbvie Inc
NYSE:ABBV
311.8B USD 15.2
US
Amgen Inc
NASDAQ:AMGN
140.7B USD 16.1
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD 20.8
US
Epizyme Inc
F:EPE
94.1B EUR -514.8
AU
CSL Ltd
ASX:CSL
134.4B AUD 19.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD 15.3
US
Seagen Inc
F:SGT
39.3B EUR -58.8
NL
argenx SE
XBRU:ARGX
36B EUR -109.5
EBITDA Growth EV/EBITDA to Growth
KR
H
Hugel Inc
KOSDAQ:145020
Average EV/EBITDA: 16.5
18
113%
0.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.8
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.5 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
16.9
2-Years Forward
EV/EBITDA
13.5
3-Years Forward
EV/EBITDA
11.1

See Also

Discover More